Brief: Beyondspring Subsidiary, Seed Therapeutics, Announces Research Collaboration And License Agreement With Lilly
13/11/2020 12:09
Nov 13 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING SUBSIDIARY, SEED THERAPEUTICS, ANNOUNCES
RESEARCH
COLLABORATION AND LICENSE AGREEMENT WITH LILLY
* SEED THERAPEUTICS - TO USE PROPRIETARY "MOLECULAR GLUE"
PROTEIN
DEGRADATION TECHNOLOGY TO DEVELOP POTENTIAL NEW MEDICINES
* SEED THERAPEUTICS - WILL RECEIVE A $10 MILLION UPFRONT
CASH
PAYMENT TO FUND RESEARCH, AS WELL AS A $10 MILLION EQUITY
INVESTMENT FROM LILLY
* SEED THERAPEUTICS - WILL ALSO BE ELIGIBLE TO RECEIVE UP TO
ABOUT
$780 MILLION IN POTENTIAL MILESTONES, UNDER DEAL WITH LILLY
Source text for Eikon: ID:nGNXc7pSvF
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value